ViGenCell Inc. (KOSDAQ:308080)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,960.00
+45.00 (1.54%)
At close: Jun 16, 2025, 3:30 PM KST
-23.61%
Market Cap 60.32B
Revenue (ttm) 278.95M
Net Income (ttm) -12.56B
Shares Out 20.45M
EPS (ttm) -650.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 35,997
Average Volume 34,964
Open 2,920.00
Previous Close 2,915.00
Day's Range 2,915.00 - 2,985.00
52-Week Range 2,305.00 - 4,560.00
Beta 1.10
RSI 47.12
Earnings Date Aug 14, 2025

About ViGenCell

ViGenCell Inc. specializes in immune cell therapy. It develops ViTier, a T-cell therapy platform that uses antigen-specific killer T cells to target and remove cancer cells; ViRanger, a T-cell gene therapy platform that uses innate killer T cells to target and eliminate abnormal cells; and ViMedier, an immunosuppressive cell therapy platform that uses the differentiation and expansion of cord blood derived myeloid suppressor cells for universal use. The company was founded in 1995 and is based in Seoul, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1995
Employees 64
Stock Exchange KOSDAQ
Ticker Symbol 308080
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.